Transitioning from Once-Monthly to Once-Every-3-Months Paliperidone Palmitate Among Veterans with Schizophrenia

Antoine C El Khoury,1 Charmi Patel,1 Panagiotis Mavros,1 Ahong Huang,2 Li Wang,2 Richa Bashyal2 1Janssen Scientific Affairs, LLC, Titusville, NJ, USA; 2STATinMED Research, Plano, TX, USACorrespondence: Antoine C El KhouryJanssen Scientific Affairs, LLC, 1125 Trenton-Harbourton Road, Titusville, NJ,...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	El Khoury AC, Patel C, Mavros P, Huang A, Wang L, Bashyal R
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2021
Materias:	long-acting injectable antipsychotic adherence healthcare resource utilization cost Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429
Acceso en línea:	https://doaj.org/article/7de5e7c224a949509cabd1970813a41e
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:7de5e7c224a949509cabd1970813a41e
record_format	dspace
spelling	oai:doaj.org-article:7de5e7c224a949509cabd1970813a41e2021-12-02T19:21:59ZTransitioning from Once-Monthly to Once-Every-3-Months Paliperidone Palmitate Among Veterans with Schizophrenia1178-2021https://doaj.org/article/7de5e7c224a949509cabd1970813a41e2021-10-01T00:00:00Zhttps://www.dovepress.com/transitioning-from-once-monthly-to-once-every-3-months-paliperidone-pa-peer-reviewed-fulltext-article-NDThttps://doaj.org/toc/1178-2021Antoine C El Khoury,1 Charmi Patel,1 Panagiotis Mavros,1 Ahong Huang,2 Li Wang,2 Richa Bashyal2 1Janssen Scientific Affairs, LLC, Titusville, NJ, USA; 2STATinMED Research, Plano, TX, USACorrespondence: Antoine C El KhouryJanssen Scientific Affairs, LLC, 1125 Trenton-Harbourton Road, Titusville, NJ, 08560, USATel +1 609-737-2699Email akhour@its.jnj.comPurpose: Compared to once-monthly paliperidone palmitate (PP1M), once-every-3-months paliperidone palmitate (PP3M) reportedly increases treatment adherence. The objective of this study was to compare treatment patterns, utilization, and costs among Veterans Health Administration (VHA) patients with schizophrenia who transitioned to PP3M versus those remaining on PP1M.Patients and Methods: Adult VHA patients with ≥ 2 health care encounters (inpatient or outpatient) that included a schizophrenia diagnosis who initiated PP1M between January 1, 2015, and March 31, 2018 (identification period) were included in this exploratory retrospective cohort study. Propensity scores were used to match cases (PP1M users who transitioned to PP3M during the identification period) with controls (any patient initiating PP1M during the identification period). Data were assessed until death, health plan disenrollment, or study end. Outcomes were compared using chi-square and t-tests.Results: A total of 257 eligible PP3M and 2973 eligible PP1M patients were identified among adult VHA patients; mean ages were 53.1 and 53.7 years, respectively. After propensity score matching, the PP3M and PP1M cohorts each held 111 patients. Comorbidities of patients treated with PP3M versus PP1M, respectively, included anxiety (12.5% vs 20%; standardized difference [STD] = 20.6), tobacco use (28.4% vs 43.2%; STD = 31.2), depressive disorder (26.5% vs 36.2%; STD = 21.1), and substance abuse (37.4% vs 44.2%; STD = 13.9). For the PP3M cohort, adherence (proportion of days covered ≥ 80%) to any antipsychotic agent was higher (78.4% vs 57.7%, P = 0.0009), and all-cause inpatient lengths of stay (LOS) were shorter (3.0 vs 8.3 days, P = 0.0354). Increased all-cause pharmacy costs with PP3M were offset by reduced all-cause medical costs, resulting in overall health care cost-neutrality.Conclusion: Relative to those remaining on PP1M, VHA patients with schizophrenia who transitioned to PP3M experienced improved antipsychotic medication adherence and significantly shorter all-cause inpatient LOS; costs remained neutral.Keywords: long-acting injectable antipsychotic, adherence, healthcare resource utilization, costEl Khoury ACPatel CMavros PHuang AWang LBashyal RDove Medical Pressarticlelong-acting injectable antipsychoticadherencehealthcare resource utilizationcostNeurosciences. Biological psychiatry. NeuropsychiatryRC321-571Neurology. Diseases of the nervous systemRC346-429ENNeuropsychiatric Disease and Treatment, Vol Volume 17, Pp 3159-3170 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	long-acting injectable antipsychotic adherence healthcare resource utilization cost Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429
spellingShingle	long-acting injectable antipsychotic adherence healthcare resource utilization cost Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429 El Khoury AC Patel C Mavros P Huang A Wang L Bashyal R Transitioning from Once-Monthly to Once-Every-3-Months Paliperidone Palmitate Among Veterans with Schizophrenia
description	Antoine C El Khoury,1 Charmi Patel,1 Panagiotis Mavros,1 Ahong Huang,2 Li Wang,2 Richa Bashyal2 1Janssen Scientific Affairs, LLC, Titusville, NJ, USA; 2STATinMED Research, Plano, TX, USACorrespondence: Antoine C El KhouryJanssen Scientific Affairs, LLC, 1125 Trenton-Harbourton Road, Titusville, NJ, 08560, USATel +1 609-737-2699Email akhour@its.jnj.comPurpose: Compared to once-monthly paliperidone palmitate (PP1M), once-every-3-months paliperidone palmitate (PP3M) reportedly increases treatment adherence. The objective of this study was to compare treatment patterns, utilization, and costs among Veterans Health Administration (VHA) patients with schizophrenia who transitioned to PP3M versus those remaining on PP1M.Patients and Methods: Adult VHA patients with ≥ 2 health care encounters (inpatient or outpatient) that included a schizophrenia diagnosis who initiated PP1M between January 1, 2015, and March 31, 2018 (identification period) were included in this exploratory retrospective cohort study. Propensity scores were used to match cases (PP1M users who transitioned to PP3M during the identification period) with controls (any patient initiating PP1M during the identification period). Data were assessed until death, health plan disenrollment, or study end. Outcomes were compared using chi-square and t-tests.Results: A total of 257 eligible PP3M and 2973 eligible PP1M patients were identified among adult VHA patients; mean ages were 53.1 and 53.7 years, respectively. After propensity score matching, the PP3M and PP1M cohorts each held 111 patients. Comorbidities of patients treated with PP3M versus PP1M, respectively, included anxiety (12.5% vs 20%; standardized difference [STD] = 20.6), tobacco use (28.4% vs 43.2%; STD = 31.2), depressive disorder (26.5% vs 36.2%; STD = 21.1), and substance abuse (37.4% vs 44.2%; STD = 13.9). For the PP3M cohort, adherence (proportion of days covered ≥ 80%) to any antipsychotic agent was higher (78.4% vs 57.7%, P = 0.0009), and all-cause inpatient lengths of stay (LOS) were shorter (3.0 vs 8.3 days, P = 0.0354). Increased all-cause pharmacy costs with PP3M were offset by reduced all-cause medical costs, resulting in overall health care cost-neutrality.Conclusion: Relative to those remaining on PP1M, VHA patients with schizophrenia who transitioned to PP3M experienced improved antipsychotic medication adherence and significantly shorter all-cause inpatient LOS; costs remained neutral.Keywords: long-acting injectable antipsychotic, adherence, healthcare resource utilization, cost
format	article
author	El Khoury AC Patel C Mavros P Huang A Wang L Bashyal R
author_facet	El Khoury AC Patel C Mavros P Huang A Wang L Bashyal R
author_sort	El Khoury AC
title	Transitioning from Once-Monthly to Once-Every-3-Months Paliperidone Palmitate Among Veterans with Schizophrenia
title_short	Transitioning from Once-Monthly to Once-Every-3-Months Paliperidone Palmitate Among Veterans with Schizophrenia
title_full	Transitioning from Once-Monthly to Once-Every-3-Months Paliperidone Palmitate Among Veterans with Schizophrenia
title_fullStr	Transitioning from Once-Monthly to Once-Every-3-Months Paliperidone Palmitate Among Veterans with Schizophrenia
title_full_unstemmed	Transitioning from Once-Monthly to Once-Every-3-Months Paliperidone Palmitate Among Veterans with Schizophrenia
title_sort	transitioning from once-monthly to once-every-3-months paliperidone palmitate among veterans with schizophrenia
publisher	Dove Medical Press
publishDate	2021
url	https://doaj.org/article/7de5e7c224a949509cabd1970813a41e
work_keys_str_mv	AT elkhouryac transitioningfromoncemonthlytoonceevery3monthspaliperidonepalmitateamongveteranswithschizophrenia AT patelc transitioningfromoncemonthlytoonceevery3monthspaliperidonepalmitateamongveteranswithschizophrenia AT mavrosp transitioningfromoncemonthlytoonceevery3monthspaliperidonepalmitateamongveteranswithschizophrenia AT huanga transitioningfromoncemonthlytoonceevery3monthspaliperidonepalmitateamongveteranswithschizophrenia AT wangl transitioningfromoncemonthlytoonceevery3monthspaliperidonepalmitateamongveteranswithschizophrenia AT bashyalr transitioningfromoncemonthlytoonceevery3monthspaliperidonepalmitateamongveteranswithschizophrenia
_version_	1718376746955309056

Transitioning from Once-Monthly to Once-Every-3-Months Paliperidone Palmitate Among Veterans with Schizophrenia

Ejemplares similares